
Sacubitril/valsartan over 12 weeks compared with enalapril did not significantly improve peak oxygen consumption (VO2) in patients with heart failure with reduced ejection fraction (HFrEF). CI, confidence interval; LSM, least squares mean; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SE, standard error. ACTIVITY‐HF was a randomized, double‐blind, active‐controlled study, which assessed the short‐term effect of sacubitril/valsartan compared with the active comparator enalapril on improving maximal exercise capacity in patients with heart failure with reduced ejection fraction (HFrEF)...
Like
Save
Share